Abstract

The calcitonin gene-related peptide (CGRP) suppresses fear memory retention in mice. Although intracerebroventricular administration of CGRP alters the fear memory processes, making it a promising therapeutic strategy for post-traumatic stress disorder (PTSD), direct brain injection into patients is not practical. Therefore, we propose that intranasal application may be an effective way to deliver CGRP to the brain. This study tested whether CGRP nasal administration exerts the same effect as intracerebroventricular administration using C57BL6J mice. The amount of CGRP in the cerebrospinal fluid and hippocampus 30 min after nasal administration of CGRP was significantly higher when compared with saline. Intranasal CGRP also elicited photophobic behaviors similar to intracerebroventricular injection. Moreover, intranasal CGRP decreased fear memory retention but did not affect reactivation and extinction of fear memory. We found intranasal CGRP significantly increased the expression of protein kinase D (PKD), phosphorylated histone deacetylase 5 (p-HDAC5) and neuronal PAS domain protein 4 (Npas4) in the hippocampus. CGRP-mediated impairment of fear memory and Npas4 expression increases were attenuated significantly by the CGRP receptor antagonist BIBN4096. Together, our data demonstrate that intranasal CGRP delivery activates the PKD/p-HDAC5/Npas4 pathway, decreases fear memory retention.

Highlights

  • The calcitonin gene-related peptide (CGRP) suppresses fear memory retention in mice

  • We focused on CGRP signaling via the protein kinase D (PKD)/phosphorylated histone deacetylase 5 (p-HDAC5)/neuronal PAS domain protein 4 (Npas4) pathway in the mouse hippocampus

  • CGRP administration on memory retention deficits, we focused on Npas[4], which is a transcription factor that has a well-established role in fear memory ­processing[16]

Read more

Summary

Introduction

The calcitonin gene-related peptide (CGRP) suppresses fear memory retention in mice. Intracerebroventricular administration of CGRP alters the fear memory processes, making it a promising therapeutic strategy for post-traumatic stress disorder (PTSD), direct brain injection into patients is not practical. We found intranasal CGRP significantly increased the expression of protein kinase D (PKD), phosphorylated histone deacetylase 5 (p-HDAC5) and neuronal PAS domain protein 4 (Npas4) in the hippocampus. Our data demonstrate that intranasal CGRP delivery activates the PKD/p-HDAC5/Npas[4] pathway, decreases fear memory retention. Our previous studies have reported that intracerebroventricular (i.c.v.) administration of CGRP immediately after fear memory exposure impairs fear memory retention in C57BL6J ­mice[3]. We found that i.n. CGRP application suppresses fear memory retention and increases Npas[4] expression via CGRP receptor activation. CGRP administration could be a viable potential alternative to direct brain injection for delivering CGRP to PTSD patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call